Rosetta Genomics and 2 NASDAQ Top Percentage Losers

| + More Articles
  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

Rosetta Genomics Ltd. (NASDAQ:ROSG): Positive news came at a price for Rosetta Genomics. The company announced that a recent study published in The Oncologist demonstrated the ability of the miRview mets2assay to identify 42 tumor types with high accuracy and maintain the same performance in samples from patients clinically diagnosed with CUP. Upon the news, the firm’s stock has gone up tenfold since May 16 and more than doubled in just the past two days. Rosetta Genomics said it will sell 570,755 shares to investors at $11.50/share, a 29% discount to its Thursday closing price. Shares closed Friday at $13.24, down 18.72%, and they have traded in a 52-week range of $1.40 to $36.45.

Mentor Graphics Corporation (NASDAQ:MENT) looks like it needs some mentoring of its own after seeing its stock tumble after missing FQ1 revenue estimates. The drop came in spite of Mentor’s FQ2 guidance (revenue of $240M and EPS of $0.17), which was largely in-line with estimates,and its FY13 EPS guidance $0.04 above its $1.33 consensus. Mentor shares fell 13.21% to $13.20, and they have traded in a 52-week range of $8.50 to $15.76.

Maxwell Technologies, Inc. (NASDAQ:MXWL) is seeing new multi-year lows after a downgrade to Neutral from Wedbush. The firm said the news indicates new competition in Maxwell’s ultracapacitor business from China’s Lishen, also adding that it believes Lishen’s sales flies in the face of its outsourcing partnership. Maxwell shares dipped 12.01% to $6.96, and they have traded in a 52-week range of $7.60 to $21.49.

Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.

More Articles About:

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business